Related Experiment Video

Updated: Mar 11, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Polymorphism of the complement 5 gene is associated with large artery atherosclerosis stroke in Chinese patients

Hui Wu1, Yingfeng Weng1, Lan Zheng1

  • 1Minhang District Central Hospital, Department of Neurology, Shanghai, China.

Arquivos De Neuro-Psiquiatria
|December 1, 2016
PubMed

Insights

The C5 rs17611 genetic variant is linked to an increased risk of large artery atherosclerosis (LAA) ischemic stroke (IS). This genetic factor may independently contribute to LAA-IS incidence.

Area of Science:

  • Genetics
  • Neurology
  • Cardiovascular Research

Background:

  • Ischemic stroke (IS) is a leading cause of disability and death.
  • Identifying genetic risk factors for IS subtypes is crucial for targeted prevention.
  • The role of specific genetic polymorphisms, such as C5 rs17611, in IS remains under investigation.

Purpose of the Study:

  • To investigate the association between C5 rs17611 genetic variants and the risk of ischemic stroke.
  • To determine if C5 rs17611 influences the incidence of specific IS subtypes, particularly large artery atherosclerosis (LAA).
  • To evaluate the relationship between C5 rs17611 genotypes and stroke severity or outcome.

Main Methods:

  • A case-control study involving 494 IS patients and 330 healthy controls.
  • Genotyping for C5 rs17611 variants was performed.
  • Ischemic stroke was classified into subtypes, and patients were assessed using the modified Rankin Scale (mRS) for stroke outcome.

Main Results:

  • The C5 rs17611 polymorphism was significantly associated with the incidence of the LAA-subtype IS (p = 0.031).
  • This association remained significant after adjusting for potential confounding factors (OR = 1.518, p = 0.013).
  • No significant association was found between C5 rs17611 genotypes and stroke severity or 90-day outcome (p > 0.29).

Conclusions:

  • The C5 rs17611 polymorphism may be an independent risk factor for developing large artery atherosclerosis ischemic stroke.
  • Further research is warranted to elucidate the precise mechanisms by which C5 rs17611 influences LAA-IS.
  • These findings contribute to understanding the genetic underpinnings of ischemic stroke subtypes.
Abstract

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
677
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.3K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57